Lisata Therapeutics, Inc.

Welcome to the La Sada Therapeutics second quarter 2024 financial results and business update conference call. Currently, all participants are in a listen-only mode. Following management's prepared remarks, we will hold a question and answer session. To ask a question at that time, please press star 1-1 on your telephone. You will then hear an automated message advising you that your hand is raised. As a reminder, this call is being recorded today, Monday, August 12, 2024. I will now turn the call over to John Mendito, Vice President of Investor Relations and Corporate Communications at Lasada. Please go ahead, sir.

Thank you, Operator, and good afternoon, everyone. Welcome to Lasada's second quarter 2024 conference call to discuss our financial results and to provide a business update. Joining me from our management team are Dr. David Mazzo, President and Chief Executive Officer, Dr. Kristen Buck, Executive Vice President of Research and Development and Chief Medical Officer, and James Nisko, Senior Vice President of Finance and Treasury and Chief Accounting Officer. Shortly before this call, we issued a press release announcing our second quarter 2024 financial results, which is available under the Investors and News section of the company website, along with a webcast replay of this call. If you have not received this news release or if you'd like to be added to the company's email distribution list, please subscribe to email alerts on the company website or email me at jmindido at lasada.com to be added. Before we begin, I will remind you that comments made by management during this conference call will contain forward-looking statements that involve risks and uncertainties regarding the operations and future results of Lasada. I encourage you to review the company's filings with the Securities and Exchange Commission, including without limitation its forms 10Q, 8K, and 10K, which identify specific risk factors that may cause actual results or events to differ materially from those described in the forward-looking statements. Furthermore, the content of this conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, Monday, August 12, 2024. La Sada Therapy undertakes no obligation to revise or update any statements to reflect events or circumstances after the date of this conference call. With that, I will now turn the call over to Dr. Mazzo. Dave?

Thank you, John, and good afternoon, everyone. I'm delighted to be with you today to provide an overview of recent business highlights, discuss our second quarter 2024 financial results, and give an update on the progress of our clinical development programs. During the second quarter of this year, La Sada maintained strong momentum in the advancement of our development pipeline centered around our novel investigational product, Certepratide, in combination with a variety of anti-cancer agents of differing modalities for the treatment of advanced solid tumors. As we have previously reported, consistently encouraging preclinical data as well as early clinical data in humans continue to support our belief that Certepratide has the potential to become an integral part of a revised standard of care treatment for many challenging solid tumors. Dr. Kristin Buck, our Executive Vice President of Research and Development and Chief Medical Officer, will provide a detailed update of our ongoing and planned clinical programs following the financial results review. With that, I will now turn the call over to James Nisko, our Senior Vice President of Finance and Treasury and Chief Accounting Officer. James?